

HETEROCYCLES, Vol. 71, No. 8, 2007, pp. 1843 - 1849. © The Japan Institute of Heterocyclic Chemistry  
Received, 18th April, 2007, Accepted, 23rd May, 2007, Published online, 25th May, 2007. COM-07-11084

## SYNTHESIS OF ENANTIOMERICALLY PURE (+)- AND (-)-3-METHYL-3-(2-NAPHTHYL)-2H-BENZO[*e*][1,2]THIAZINE 1,1,4-TRIONES

Zhao-Peng Liu\*

Department of Organic Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, P. R. China

E-mail: liuzhaop@sdu.edu.cn

**Abstract** – Treatment of *N-t*-butylbenzenesulfonamide with an excess of BuLi, followed by the reaction with methyl 2-naphthylpropanoate, gave the corresponding 2-carboxybenzenesulfonamide, which underwent cyclization under TMSCl-NaI-MeCN reflux conditions to afford the *N*-sulfonylimine. Bromination of the *N*-sulfonylimine and ring expansion mediated by 20% KOH (aq.), formed the 3-methyl-3-(2-naphthyl)benzo[*e*][1,2]thiazine 1,1,4-trione. Optical resolution of the racemic benzosultam using (–)-menthoxyacetyl chloride, furnished the (+)- and (–)-3-methyl-3-(2-naphthyl)benzo[*e*][1,2]thiazine 1,1,4-triones.

### 1. INTRODUCTION

1,2-Benzisothiazoline-3-one 1,1-dioxide (**1**), known as saccharin, is a cheap and versatile starting material for the synthesis of related heterocyclic compounds.<sup>1</sup> *N*-Alkylated saccharin derivatives act as agonists of 5-HT<sub>1A</sub> receptors<sup>2</sup> and have therefore found applications as neuroprotectants<sup>3</sup> or anxiolytics (e.g., Ipsapirone **2**).<sup>4</sup> They also selectively inhibit human leukocyte elastase<sup>5</sup> or human mast cell tryptase.<sup>6</sup> The oxicam ring system **3**, which can be regarded as the enol form of one carbon-extended homologue of saccharin derivatives, is a common substructure of certain pharmaceutically important antiinflammatory agents.<sup>7</sup> Oxicams can conveniently be derived from 1,2-benzisothiazoline-3-one 1,1-dioxide (saccharin) (**1**) system by ring expansion.<sup>8-10</sup> Surprisingly, 3,3-disubstituted-2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones, the one carbon-extended homologue of saccharin derivatives, have remained mostly unexplored both biologically and chemically. There are few reports on the synthesis of *N*-alkylated 3,3-disubstituted-2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones,<sup>11-12</sup> but the difficulty in removing the alkyl protective group limits their further derivatization. To our best knowledge, the literature gives three references<sup>13-14</sup> to the preparation of 3,3-disubstituted-2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones, and the only

known compounds are 3-ethyl-3-methyl-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione (**4**)<sup>13-14</sup> and 6-methoxy-3,3-dimethyl-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione.<sup>15</sup> We proved previously that introducing a carbonyl functional group in the 4-position made the *N*-fluorobenzosultam (**5**) more reactive for the electrophilic fluorination of carbanions.<sup>16</sup> However, the little difference in steric bulkiness of ethyl and methyl group in sultam **4** made it unsuitable as a template for the developing of chiral electrophilic fluorinating agent. Therefore, it is of interest to synthesis chiral 2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones having a bulky substituent and a small one at the 3-position. Also considering that Oppolzer's saccharin derived benzosultams are useful chiral auxiliaries in asymmetric organic reactions,<sup>1</sup> plus the importance of chirality in pharmacologically and biologically active compounds, we report here the first synthesis of enantiomerically pure 3-methyl-3-(2-naphthyl)benzo[*e*][1,2]thiazine 1,1,4-triones.





Figure 1


## 2. RESULTS AND DISCUSSION

The sulfonamide functionality is regarded as a powerful Directed Metalation Group (DMG) because of its ability to direct metalation to specific positions on the aryl ring. The resulting lithiated species also couple excellently with a variety of electrophiles.<sup>17</sup> The carboxylation of *o*-lithiobenzenesulfonamides is a convenient method for preparing 2-carboxybenzenesulfonamides that function as the standard intermediates for the synthesis of saccharin-related heterocycles.<sup>18</sup> By adopting a similar strategy, *N*-*t*-butylbenzenesulfonamide was treated with an excess of BuLi (2.5 eq) in THF solution at 0 °C, *ortho*-lithiation occurred smoothly with the solution changing to deep red. The formed anion reacted with methyl 2-(2-naphthyl)propanoate to give the corresponding 2-carboxybenzenesulfonamide **6** in 65% yield. The application of our TMSCl-NaI-MeCN system for deprotective-cyclization<sup>19-21</sup> of the sulfonamide **6** under reflux conditions, successfully produced 3-[2-(2-naphthyl)ethyl]benzo[*d*]isothiazole 1,1-dione (**7**) in 81% yield (Scheme 1). The *N*-sulfonylimine **7** was converted to the racemic 3,3-disubstituted-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione according to the Abramovitch's procedures.<sup>13-14</sup> Bromination of the *N*-sulfonylimine **7** in benzene gave the desired product **8** quantitatively, which underwent ring expansion mediated by 20% KOH (aq.) to form 3-methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione **9** in excellent yield.



Scheme 1

Optical resolution of sultam **9** was carried out by derivatization with (-)-menthoxyacetyl chloride followed by the separation of the two diastereomers (+)-**10a** (more polar) and (-)-**10b** (less polar) using column chromatography on silica gel. Removal of the chiral auxiliaries of (+)-**10a** and (-)-**10b** was achieved smoothly with LiOH in aqueous THF to furnish (+)-**9** and (-)-**9** respectively in an optically pure state (Scheme 2). Unfortunately, due to the poor crystal properties of compounds (+)-**10a**, (-)-**10b** and (+)-**9**, (-)-**9**, the absolute stereochemistry of these compounds could not be determined by X-ray crystallography.



Scheme 2

In conclusion, a convenient method has been developed for the synthesis of (+)- and (-)-3-methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones. It is the first report on the synthesis of chiral 3,3-disubstituted-2*H*-benzo[*e*][1,2]thiazine 1,1,4-triones. Optically pure benzosultams (+)-**9** and (-)-**9** would be useful chiral auxiliaries for asymmetric synthesis.

## EXPERIMENTAL

Melting points were determined on an X-6 micro-melting point apparatus (Beijing Tech. Co., Ltd) and are uncorrected. IR spectra ( $\text{cm}^{-1}$ ) were recorded on a Perkin-Elmer 1600 spectrometer.  $^1\text{H}$  NMR (300 MHz) spectra were recorded at rt for  $\text{CDCl}_3$  solutions. All chemical shifts were reported as  $\delta$  values (ppm) relative to  $\text{Me}_4\text{Si}$  (0.00 ppm) as internal standards for  $^1\text{H}$  spectra. Mass spectra and high-resolution spectra were recorded on a JEOL JMS D-300 mass spectrometer. Optical rotations were determined by using a Jasco DIP-370 digital polarimeter. Microanalyses were performed with a YANAKO CHN-coder MT-5. Column chromatography was performed on silica gel (200-300 mesh). All reactions involving oxygen- or moisture-sensitive compounds were carried out under a dry  $\text{N}_2$  atmosphere. Unless otherwise noted, reagents were added by syringe. THF was distilled from sodium/benzophenone immediately prior to use.

***N*-*t*-Butyl-2-(2-naphthalen-2-yl-propionyl)benzenesulfonamide (6).** To a stirred solution of *N*-*t*-butylbenzenesulfonamide (5.8 g, 27.2 mmol) in THF (150 mL) was slowly added a 1.60 M solution of BuLi in hexane (42.5 mL, 68 mmol) under nitrogen at 0 °C. The reaction mixture was stirred at 0 °C for an additional 30 min. A solution of methyl 2-naphthylpropanoate (6.11 g, 28.5 mmol) in 20 mL THF was added. After 2 h, saturated aqueous  $\text{NH}_4\text{Cl}$  was added. The mixture was extracted with EtOAc, the combined organic layers were washed with brine, dried ( $\text{MgSO}_4$ ) and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give compound **6** (6.97 g, 65%) as a white solid: mp 141 °C (EtOAc/hexane); IR (KBr) 3309, 1693  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR  $\delta$  1.26 (s, 9H), 1.66 (d,  $J = 6.9$  Hz, 3H), 4.55 (q,  $J = 6.9$  Hz, 1H), 5.24 (s, 1H), 7.02 (d,  $J = 7.6$  Hz, 1H), 7.32 (t,  $J = 7.6$  Hz, 1H), 7.42–7.54 (m, 4H), 7.75 (s, 1H), 7.79–7.90 (m, 3H), 8.02 (d,  $J = 7.9$  Hz, 1H); MS  $m/z$  395 ( $\text{M}^+$ ); HRMS calcd for  $\text{C}_{23}\text{H}_{25}\text{NO}_3\text{S}$  395.1556, found 395.1566. Anal. Calcd for  $\text{C}_{23}\text{H}_{25}\text{NO}_3\text{S}$ : C, 69.84; H, 6.37; N, 3.54. Found: C, 69.71; H, 6.31; N, 3.47.

**3-(2-Naphthylethyl)benzo[*d*]isothiazole 1,1-dione (7).** To a stirred solution of **6** (6.97 g, 17.6 mmol) in MeCN (80 mL) was added under nitrogen sodium iodide (5.28 g, 35.2 mmol) and chlorotrimethylsilane (4.50 mL, 35.2 mmol). The reaction mixture was refluxed for 1 h. It was cooled to rt and 10% sodium thiosulfate aqueous solution was added. The mixture was extracted with EtOAc, and the combined organic layers were washed with water, brine, dried ( $\text{MgSO}_4$ ) and concentrated in vacuo. Crystallization from hexane gave *N*-sulfonylimine **7** (4.56 g, 81%) as colorless prisms: mp 156 °C (EtOAc/hexane); IR (KBr) 3021, 1314, 1217, 1174  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR  $\delta$  1.81 (d,  $J = 6.9$  Hz, 3H), 4.61 (q,  $J = 6.6$  Hz, 1H), 7.42–7.50 (m, 5H), 7.58–7.61 (m, 1H), 7.79–7.88 (m, 5H); MS  $m/z$  321 ( $\text{M}^+$ ); HRMS calcd for  $\text{C}_{19}\text{H}_{15}\text{NO}_2\text{S}$  321.0824, found 321.0813. Anal. Calcd for  $\text{C}_{19}\text{H}_{15}\text{NO}_2\text{S}$ : C, 71.00; H, 4.70; N, 4.36. Found: C, 70.72; H, 4.64; N, 4.15.

**3-[1-Bromo-1-(2-naphthyl)ethyl]benzo[*d*]isothiazole 1,1-dione (8).** To a stirred solution of **7** (2.94 g, 9.16 mmol) in benzene (60 mL) was added dropwise a solution of bromine (0.47 mL, 9.16 mmol) in benzene (10 mL) at rt. The reaction mixture was stirred for 1 h. 10% sodium sulfite aqueous solution was added. The mixture was extracted with EtOAc, the combined organic layers were washed with brine, dried (MgSO<sub>4</sub>) and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give **8** (3.6 g, 98%) as a white solid: mp 65 °C (EtOAc/hexane); IR (KBr) 3023, 1346, 1275, 1178 cm<sup>-1</sup>; <sup>1</sup>H NMR δ 2.51 (s, 3H), 7.21 (d, *J* = 7.9 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.49–7.61 (m, 4H), 7.81–7.92 (m, 4H), 8.04 (br s, 1H); MS *m/z* 320 (M<sup>+</sup>–HBr). Anal. Calcd for C<sub>19</sub>H<sub>14</sub>NO<sub>2</sub>SBr: C, 57.01; H, 3.53; N, 3.50. Found: C, 57.02; H, 3.67; N, 3.40.

**3-Methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione (9).** To a stirred solution of **8** (3.26 g, 8.15 mmol) in THF (40 mL) was added 20% KOH aqueous solution (4.6 mL). The reaction mixture was refluxed for 1 h. After cooling to rt, 10% HCl (aq.) was added. The mixture was extracted with EtOAc, the combined organic layers were washed with brine, dried (MgSO<sub>4</sub>) and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give sultam **9** (2.73 g, 99%) as colorless glasses: mp 55 °C (EtOAc/hexane); IR (KBr) 3264, 1694 cm<sup>-1</sup>; <sup>1</sup>H NMR δ 2.11 (s, 3H), 5.54 (s, 1H), 7.46–7.50 (m, 2H), 7.58 (dd, *J* = 6.9, 1.5 Hz, 1H), 7.76–7.88 (m, 7H), 8.16 (dd, *J* = 6.9, 1.5 Hz, 1H); MS *m/z* 337 (M<sup>+</sup>); HRMS calcd for C<sub>19</sub>H<sub>15</sub>NO<sub>2</sub>S 337.0773, found 337.0768. Anal. Calcd for C<sub>19</sub>H<sub>15</sub>NO<sub>3</sub>S: C, 67.64; H, 4.48; N, 4.15. Found: C, 67.60; H, 4.57; N, 3.91.

***N*-Menthoxyacetyl-3-methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione (10).** A solution of **9** (2.82 g, 8.36 mmol) in THF (40 mL) was treated with NaH (60% oil dispersion, 0.5 g, 12.5 mmol) at 0 °C and stirred at rt for 1.5 h. (–)-Menthoxyacetyl chloride (2.34 g, 10 mmol) in THF (5 mL) was added to the mixture and stirred for overnight. Cold saturated aqueous NH<sub>4</sub>Cl was added, and the resulting mixture was extracted with EtOAc. The combined organic layer was washed with water, brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The residue was chromatographed (25% CH<sub>2</sub>Cl<sub>2</sub> in hexane) to give the less polar isomer (–)-**10b** (2.04 g, 46%), the more polar isomer (+)-**10a** (1.79 g, 40%) as a white powder.

(–)-***N*-Menthoxyacetyl-3-methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione [(–)-10b]:** colorless prisms; mp 160 °C; [α]<sub>D</sub><sup>26</sup> –69.3 (*c* 0.88, CHCl<sub>3</sub>); IR (KBr) 1710 cm<sup>-1</sup>; <sup>1</sup>H NMR δ 0.69 (d, *J* = 6.9 Hz, 3H), 0.80 (d, *J* = 10.2 Hz, 3H), 0.82 (d, *J* = 9.9 Hz, 1H), 0.77–0.98 (m, 2H), 1.18–1.23 (m, 2H), 1.51–1.60 (m, 3H), 1.92–1.96 (m, 1H), 2.09–2.12 (m, 1H), 2.58 (s, 3H), 3.06 (td, *J* = 10.5, 3.9 Hz, 1H), 4.46, 4.66 (ABq, *J* = 16.1, 2H), 7.05 (dd, *J* = 6.9, 1.9 Hz, 1H), 7.40–7.45 (m, 2H), 7.56–7.73 (m, 6H), 7.83 (t, *J* = 7.6 Hz, 1H), 8.02 (d, *J* = 7.3 Hz, 1H); MS *m/z* 533 (M<sup>+</sup>); HRMS calcd for C<sub>31</sub>H<sub>35</sub>NO<sub>5</sub>S

533.2236, found 533.2242. Anal. Calcd for  $C_{31}H_{35}NO_5S$ : C, 69.77; H, 6.61; N, 2.62. Found: C, 69.87; H, 6.53; N, 2.59.

**(+)-*N*-Menthoxyacetyl-3-methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione [(+)-10a]**: mp 59–61 °C;  $[\alpha]_D^{27} +3.6$  (*c* 1.46,  $CHCl_3$ ); IR (KBr) 1711  $cm^{-1}$ ;  $^1H$  NMR  $\delta$  0.51 (d, *J* = 7.0 Hz, 3H), 0.77 (d, *J* = 7.0 Hz, 3H), 0.88 (d, *J* = 6.6 Hz, 1H), 0.76–0.89 (m, 3H), 1.18–1.22 (m, 1H), 1.50–1.60 (m, 3H), 1.95–1.99 (m, 1H), 2.12–2.15 (m, 1H), 2.57 (s, 3H), 2.99 (td, *J* = 10.5, 3.9 Hz, 1H), 4.55, 4.66 (ABq, *J* = 16.8, 2H), 7.07 (dd, *J* = 7.0, 1.9 Hz, 1H), 7.40–7.44 (m, 2H), 7.58–7.74 (m, 6H), 7.84 (t, *J* = 7.6 Hz, 1H), 8.04 (d, *J* = 7.6 Hz, 1H); MS *m/z* 533 ( $M^+$ ); HRMS calcd for  $C_{31}H_{35}NO_5S$  533.2236, found 533.2227. Anal. Calcd for  $C_{31}H_{35}NO_5S$ : C, 69.77; H, 6.61; N, 2.62. Found: C, 70.06; H, 6.64; N, 2.52.

**(+)-3-Methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione [(+)-9]**. A solution of (–)-10b (2.31 g, 4.33 mmol) in THF (20 mL) was treated with 2 M LiOH (11 mL) at rt and stirred for 2 h. The mixture was poured into 10% HCl aqueous solution and extracted with EtOAc. The combined organic layer was washed with water, brine, dried ( $MgSO_4$ ), and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give (+)-9 (1.45 g, 99%) as colorless glasses: mp 65–67 °C;  $[\alpha]_D^{27} +42.1$  (*c* 0.84,  $CHCl_3$ ). Anal. Calcd for  $C_{19}H_{15}NO_3S$ : C, 67.64; H, 4.48; N, 4.15. Found: C, 67.44; H, 4.55; N, 3.96. The optical pure (+)-9 exhibited the same spectral properties (IR, MS,  $^1H$  NMR) as the racemic 9.

**(–)-3-Methyl-3-(2-naphthyl)-2*H*-benzo[*e*][1,2]thiazine 1,1,4-trione [(–)-9]**. In the same way, 1.31 g (4.33 mmol) of (+)-10a was treated with 2 M LiOH aqueous solution (11 mL) to give (–)-9 (1.39 g, 95%) as colorless glasses:  $[\alpha]_D^{26} -42.8$  (*c* 1.04,  $CHCl_3$ ). The optical pure (–)-9 exhibited the same spectral properties (IR, MS,  $^1H$  NMR) as (+)-9.

## ACKNOWLEDGEMENTS

This work was supported by the Scientific Research Foundation for the Returned Oversea Chinese Scholars of Shandong University and National Science Foundation of China.

## REFERENCES

1. See recent review: Z.-P. Liu and Y. Takeuchi, *Heterocycles* 2002, **56**, 693.
2. G. Caliendo, F. Fiorino, E. Perissutti, B. Severino, S. Gessi, E. Cattabriga, P. A. Borea, and V. Santagada, *Eur. J. Med. Chem.*, 2001, **36**, 873.
3. *Drugs Future*, 1997, **22**, 341.
4. *Drugs Future*, 1986, **11**, 565.
5. K. D. Combrink, H. B. Gulgeze, N. A. Meanwell, B. C. Pearce, P. Zulan, G. S. Bisacchi, D. G. Roberts, P. Stanley, and S. M. Seiler, *J. Med. Chem.*, 1998, **41**, 4854.

6. D. J. Hlasta, C. Subramanyam, M. R. Bell, P. M. Carabateas, J. J. Court, R. C. Desai, M. L. Drozd, W. M. Eickhoff, E. W. Ferguson, R. J. Gordon, J. A. Johnson, V. Kumar, A. L. Maycock, K. R. Mueller, E. D. Pagani, D. T. Robinson, M. T. Saindane, P. J. Silver, and S. Subramanian, *J. Med. Chem.*, 1995, **38**, 739.
7. J. G. Lombardino and E. H. Wiseman, *Med. Res. Rev.*, 1982, **2**, 127.
8. P. Catsoulacos and C. Camoutsis, *J. Heterocycl. Chem.*, 1979, **16**, 1503.
9. J. G. Lombardino and D. E. Kuhla, *Adv. Heterocycl. Chem.*, 1982, **28**, 73.
10. P. D. Weeks, F. J. Vinick, R. Breitenbach, and S. Jung, *J. Org. Chem.*, 1983, **48**, 3601.
11. D. C. Piero, D. M. Demetrio, and L. R. Concetta, *J. Chem. Soc., Perkin Trans. 1*, 1986, 299.
12. H. Zinnes and J. Shavel, Jr., *J. Heterocycl. Chem.*, 1973, **10**, 956.
13. R. A. Abramovitch, E. M. Smith, M. Humber, B. Purtschert, P. C. Srinivasan, and G. M. Singer, *J. Chem. Soc., Perkin Trans. 1*, 1974, 2589.
14. R. A. Abramovitch, K. M. More, I. Shinkai, and P. C. Srinivasan, *J. Chem. Soc., Chem. Commun.*, 1976, 771.
15. W. I. Bakker, O. B. Familoni, J. Padfield, and V. Snieckus, *Synlett*, 1997, 1019.
16. Y. Takeuchi, Z.-P. Liu, E. Suzuki, N. Shibata, and K. L. Kirk, *J. Fluorine Chem.*, 1999, **97**, 65.
17. O. B. Familoni, *Synlett*, 2002, 1181.
18. M. Takahashi, K. Ohtsuki, T. Taga, and Y. Chohnan, *Heterocycles*, 1998, **48**, 1643.
19. Z.-P. Liu, N. Shibata, and Y. Takeuchi, *J. Org. Chem.*, 2000, **65**, 7583.
20. Z.-P. Liu, N. Shibata, and Y. Takeuchi, *J. Chem. Soc., Perkin Trans. 1*, 2002, 302.
21. Z.-P. Liu, T. Toyoshi, and Y. Takeuchi, *Synth. Commun.*, 2004, **34**, 471.